EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation

被引:5
作者
Kasow, Kimberly A.
Leung, Wing
Horwitz, Edwin A.
Woodard, Paul
Handgretinger, Rupert
Hale, Gregory A.
机构
[1] St Jude Childrens Res Hosp, Dept Hematol Oncol, Div Stem Cell Transplantat, Memphis, TN 38105 USA
[2] St Jude Childrens Res Hosp, Div Expt Hematol, Memphis, TN 38105 USA
[3] Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA
关键词
allogeneic stem cell transplantation; Epstein-Barr virus; haploidentical; lymphoproliferative disorder; T-cell depletion;
D O I
10.1002/pbc.20710
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Post-transplant lymphoproliferative disease (PTLPD), due to the reactivation of Epstein-Barr virus (EBV), is a serious complication. The risk of the disorder increases with T-cell depletion methods, mismatched hematopoietic stem cell transplantation (HSCT), graft-versus-host disease (GVHD), and immunosuppression. In contrast to solid organ transplantation, where EBV is typically of recipient origin, the source of the EBV in HSCT recipients is donor-derived B-lymphocytes. in this report, we describe a 15-year-old girl who underwent HSCT from her father as treatment for acute myeloid leukemia (AML). She subsequently developed disseminated PTLPD involving multiple organ and nodal sites. Her neoplastic lymphoblasts were host-derived and refractory to rituximab treatment due to lack of CD20 expression. Pediatr Blood Cancer 2007;49:869-872. (c) 2006 Wiley-Liss, Inc.
引用
收藏
页码:869 / 872
页数:4
相关论文
共 14 条
[1]  
Curtis RE, 1999, BLOOD, V94, P2208
[2]  
DAVIS CL, 1995, CLIN TRANSPLANT, V9, P53
[3]   Post-transplant lymphoproliferative disorder in children: Incidence, prognosis, and treatment options [J].
Faye A. ;
Vilmer E. .
Pediatric Drugs, 2005, 7 (1) :55-65
[4]   Epstein-Barr virus infections: prospects for treatment [J].
Gershburg, E ;
Pagano, JS .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (02) :277-281
[5]   Transplantation of megadoses of purified haploidentical stem cells [J].
Handgretinger, R ;
Schumm, M ;
Lang, P ;
Greil, J ;
Reiter, A ;
Bader, P ;
Niethammer, D ;
Klingebiel, T .
HEMATOPOIETIC STEM CELLS: BIOLOGY AND TRANSPLANTATION, 1999, 872 :351-362
[6]   Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease [J].
Heslop, HE ;
Savoldo, B ;
Rooney, CM .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2004, 17 (03) :401-413
[7]   CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation [J].
Kuehnie, I ;
Huls, MH ;
Liu, ZS ;
Semmelmann, M ;
Krance, RA ;
Brenner, MK ;
Rooney, CM ;
Heslop, HE .
BLOOD, 2000, 95 (04) :1502-1505
[8]  
Liu Zhensheng, 2002, Recent Results Cancer Res, V159, P123
[9]   INFUSIONS OF DONOR LEUKOCYTES TO TREAT EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
PAPADOPOULOS, EB ;
LADANYI, M ;
EMANUEL, D ;
MACKINNON, S ;
BOULAD, F ;
CARABASI, MH ;
CASTROMALASPINA, H ;
CHILDS, BH ;
GILLIO, AP ;
SMALL, TN ;
YOUNG, JW ;
KERNAN, NA ;
OREILLY, RJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (17) :1185-1191
[10]   Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease [J].
Savoldo, B ;
Rooney, CM ;
Quiros- Tejeira, RE ;
Caldwell, Y ;
Wagner, HJ ;
Lee, T ;
Finegold, MJ ;
Dotti, G ;
Heslop, HE ;
Goss, JA .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (03) :566-572